Home › Funds › Redmile Group, LLC › ADCT

Redmile Group, LLC position in ADCT

ADC THERAPEUTICS SA · Health Care

Redmile Group, LLC reported holding 11,526,710 shares of ADCT (ADC THERAPEUTICS SA) in its Q2 2026 13F filing — a position valued at US$12.3M, representing 0.83% of its reported portfolio and ranking #25 among its reported holdings. Redmile Group, LLC has disclosed ADCT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)11.53M sh
Reported value held$12.33M
Portfolio Weight0.83%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Redmile Group, LLC's ADCT position evolved

Redmile Group, LLC first disclosed a stake in ADCT in Q3 2023 at 14,178,045 shares (US$12.7M). The position peaked in Q1 2024 at 15,269,217 shares, worth US$68.6M. Across 12 filings, Redmile Group, LLC increased the stake 2 time(s), trimmed it 2 time(s) and left it unchanged 7 time(s). The most recent filing (Q2 2026) shows 11,526,710 shares valued at US$12.3M — a reduction of -3,943,792 shares quarter over quarter.. Notable position changes include a 25% trim in Q2 2026 (shares rose 14% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 14.18M $12.72M New
Q4 2023 15.33M $25.45M Add
Q1 2024 15.27M $68.56M Hold
Q2 2024 15.27M $48.25M Hold
Q3 2024 15.67M $49.36M Add
Q4 2024 15.67M $31.18M Hold
Q1 2025 15.67M $22.09M Hold
Q2 2025 15.67M $41.99M Hold
Q3 2025 15.67M $62.67M Hold
Q4 2025 15.67M $55.30M Hold
Q1 2026 15.47M $58.01M Reduce
Q2 2026 11.53M $12.33M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ADCT and 13F data

ADCT (ADC THERAPEUTICS SA) is a Health Care company. 27 other funds we track also report a position in ADCT — the largest reported positions include TCG Crossover Management, LLC (US$12.2M), Prosight Management, LP (US$8.4M), Blue Owl Capital Holdings LP (US$785K). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ADCT

All ADCT fund holders →

FAQ

How long has Redmile Group, LLC held ADCT?

Redmile Group, LLC has disclosed ADCT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Redmile Group, LLC's current position in ADCT?

As of Q2 2026, Redmile Group, LLC holds 11.53M shares of ADCT (ADC THERAPEUTICS SA), valued at $12.33M, representing 0.83% of its reported portfolio and ranking #25.

Has Redmile Group, LLC been buying or selling ADCT?

In the latest 13F filing (Q2 2026), Redmile Group, LLC reduced its position in ADCT. The position peaked in Q1 2024 at 15.27M shares.

Which other funds hold ADCT?

Other major institutional holders of ADCT include TCG Crossover Management, LLC, Prosight Management, LP, Blue Owl Capital Holdings LP, among 27 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.